{"name":"Inovio Pharmaceuticals","slug":"inovio","ticker":"INO","exchange":"NASDAQ","domain":"inovio.com","description":"Inovio Pharmaceuticals, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 170 total vaccine candidates in development.","hq":"Plymouth Meeting, PA","founded":0,"employees":"112","ceo":"Jacqueline Shea","sector":"DNA Vaccines / Immunotherapy","stockPrice":1.08,"stockChange":0.03,"stockChangePercent":2.86,"marketCap":"$89M","metrics":{"revenue":42220086,"revenueGrowth":-100,"grossMargin":0,"rdSpend":54206874,"netIncome":-84945901,"cash":58512464,"dividendYield":0,"peRatio":-1.7,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2023-03-15","type":"regulatory","headline":"Inovio Receives FDA Fast Track Designation for INO-3107","summary":"Inovio Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to INO-3107, the company's DNA-based vaccine candidate for the treatment of HPV-related cancers.","drugName":"INO-3107","sentiment":"positive"},{"date":"2022-11-10","type":"earnings","headline":"Inovio Pharmaceuticals Reports Third Quarter 2022 Financial Results","summary":"Inovio Pharmaceuticals reported its financial results for the third quarter of 2022, with a net loss of $25.4 million.","drugName":"","sentiment":"neutral"},{"date":"2022-09-06","type":"deal","headline":"Inovio Pharmaceuticals Enters into Agreement with UK Government for COVID-19 Vaccine Supply","summary":"Inovio Pharmaceuticals announced that it has entered into an agreement with the UK government to supply its COVID-19 vaccine, INO-4800.","drugName":"INO-4800","sentiment":"positive"}],"realNews":[{"date":"2026-04-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgJBVV95cUxPbFdKWmg4Ym1BYmJfLThzSDZ3S3ZVUy1KZlNDbDc1UDJnSHV1clR3aEdmQUhpUkt4aS00QldBazNGLWJ5bkZISjI5aVc2MmVtZnZaMWdHaTk1Qm5Vb2cwMW5sZ3kzZUw3cG5ISHpidXg2UFVJVEotcEgxWjJXazdrcWZFdDBmWVQtYWNUMHZHQk5scjgyN0gyUmRGbVdTaVVYWmdoRS1udjBYcjR2NklMVndrblRNS1V2Rm9TQ3puTU1XSEFKaG5kU3JpZnM0T2FPSnFhMksxM0JRdWItUEdIUk02V20tMzZNZHVzVm0xQkFMUHdKc3l2M0QxWnZrM3lYVUpGV0N1NlhkbHU3WGVJSEQxOWg4dw?oc=5","date":"2026-04-04","type":"pipeline","source":"GuruFocus","summary":"INO SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds Inovio Pharm - GuruFocus","headline":"INO SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds Inovio Pharm","sentiment":"neutral"},{"date":"2026-04-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE5ZdGpjbm5kMHNKR3pCV1dQbDVuNUo4QnZKZWhJQ2UyZ0hvQXQyQ0J0ZUpJdlE1LXU3QUFIWDFKYkpKMWtHcm1feVRNazEwem1CYjNEWnFQMWE0bS1jSzJpdlVHbDJuWmFaZ2pxVQ?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Inovio Pharmaceu (INO) - Stock Titan","headline":"If You Invested $1,000 in Inovio Pharmaceu (INO)","sentiment":"neutral"},{"date":"2026-03-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-12","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxOcVBFRWI0VVJKUUtMWnlrQkxIZmdnTXhvSVpSN0ZLWHBqUG1qVEtwTVhpZTVXZXJnZ0FPQkdRakMxWkxkYXZDWEdRWHo0RWRnUDFDa0ZXOWQycFhvbzBUY3RzQVlFT1NlS0t2YXJIOTlqRW9oaXZia3N2eGdaSzQ0U1V6X2VYWkRFaG9MY0xCM19wUmNoSDl3ZjE2Sm5wemNJUHlvak5fTmZpQ0stODdsVm9hZWsxUEQ2bFQyaC1hR2xFeUY1RGxkUlBMbDY0cWRMZ2ZKTER3ekRWbDRKVzNReHN4c3FNaGRxbk1tQzZxZnNUVFZrTGdHU094djZRUVJNNFg4UExPcjNYeGlaZWlQOUlnTmdVUmhLY1dnMTlxRmhYVFp2ZUFTNm9n?oc=5","date":"2026-02-13","type":"pipeline","source":"globenewswire.com","summary":"INO Class Action Alert: Robbins LLP Reminds Investors of - globenewswire.com","headline":"INO Class Action Alert: Robbins LLP Reminds Investors of","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOTzRnaENZUTVXb0I4RVV1em1UaUNQLUQ3NGhQZzVibnlqQnFXWEd0cFhMbDhDdkJSbXNFa0RJVF9wNUE5TC12a0EzcWNjMjQ4bzRnbzNJYmJtVHp1U0dxMzE2aVJBbWdZWUkwLUExUlhZQzFVZkk4a0RSWlA1d0dzakFfbm1QNGYtWkN0Y0llTFRCV2NRZmhWWWs4NDZhU0dMSnZIbk9vVU0?oc=5","date":"2026-01-10","type":"deal","source":"Seeking Alpha","summary":"Inovio Pharmaceuticals: Speculative Buy Thesis Hinges On INO-3107 (NASDAQ:INO) - Seeking Alpha","headline":"Inovio Pharmaceuticals: Speculative Buy Thesis Hinges On INO-3107 (NASDAQ:INO)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxOc0lxZmd2d0hIWXlIcTh3RmpWS042cXZBc1FnVmRVY1VXX2tTTTliOHlVQ3NESmwyQ3d3anAxYWFXR08xaEt2NllxdEtJaHlLbmlDSlphaUJUd3ZmaWJuTEtsNVBMQ09zLW5wSDN1dGwyak1NY05MdGQxZDVPSHZMbWdPck1DNXRja3ROenpORDhiVFltU0ZkRFd5VzlGVTZ2WkNqUG1tNjVhWXJxNDBGS1hHcDRtZzJBajViZTRyUVVCemZ5T1J5LUdmaV8?oc=5","date":"2025-12-29","type":"pipeline","source":"Benzinga","summary":"Why Is Inovio Pharma Stock Sinking Monday? - Inovio Pharmaceuticals (NASDAQ:INO) - Benzinga","headline":"Why Is Inovio Pharma Stock Sinking Monday? - Inovio Pharmaceuticals (NASDAQ:INO)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxNMmkxWmxaOFFsMEtmWDVyS09FOGdmbU5NY0xHZmVBSFNvUmVJTVcxN2JpaHZETEVxVGdsTkhjaW5tOFhTcGFiZFEwaS1jbjQ1b1BPekRUa1FLZXVucndGcDhkdk9sMFJTbUsxNjlhaExtU3F0V2dRUzc4RjhXbWtmdnktSmxOdDg?oc=5","date":"2025-12-29","type":"regulatory","source":"The Pharma Letter","summary":"FDA setback gives Inovio a headache - The Pharma Letter","headline":"FDA setback gives Inovio a headache","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNOUE2U1JMMVhjZlVBcnBnWXJoeWw5OElRY0xseWtycGotUXdXWGVyLW15RGJpU1pUeko4TG1TQm85UEtROVRZTEs3NmNFWmk5UkluVGFaaVowV1VoVkU3aEI4SDZqUDR0ZGdVUEg1WTNPRlpoWnpzVHFjWHJIVTNNOE1udEo2U0VxdVN6bzZhNi1rQ0dFTXdURW4zX1J5aklwWXZzR1lESEhob0JRcy15MWg0aUMyeU5WWWV2MFJyWQ?oc=5","date":"2025-11-03","type":"pipeline","source":"Stock Titan","summary":"INOVIO (NASDAQ: INO) completes rolling BLA for INO-3107 in RRP; priority review requested - Stock Titan","headline":"INOVIO (NASDAQ: INO) completes rolling BLA for INO-3107 in RRP; priority review requested","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPM0NyZ3FGaDA3NU1OSVYyb1ZVcjZ3TFB4T0dZcHgwRGxhZHg3MW5CWWo3UElhbkxFX2JHUVV1eDN0NlFsZDZueHc5ZDA0NUFnSGI0Q1dmU1gyU2t1VDluT3YwV0dvUGNmN0VwS0hudDVqRjJXY2d5MzBpV000em8zQVNpS2k3OFptOUdVRVBQZklJcm1zZUl1Rng1TER6NVQ4Q3M5SDl5Rmx2QQ?oc=5","date":"2025-08-27","type":"pipeline","source":"Seeking Alpha","summary":"Inovio: Back On Track With INO-3107 BLA For RRP Before End Of 2025 - Seeking Alpha","headline":"Inovio: Back On Track With INO-3107 BLA For RRP Before End Of 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxNRjhBMjZnWDF6YTMtZ1RwM3hqb19BaDA1bXVNVnRRdk1iWXp6VWRsYzQ1MlZWQXVwaFZyUkl5bHNGNk9zZWRzc0hHbnZxSjJfbUpIZVJLSjAzSmhjY0YwRGJwUVVySW5IeWw2MUNKTjRQTjVwN2laSFdTVS10dm85V1BqZk9HNm5TQm5GNGFZT0VjVzg4b3lGeUJ2eHJBTjQzQ2VzMEZsQlhGMjhtcXd1VHZoS2NPdVpxWG1RbXZrem5SUlpxenNOdEE3SXhDa0M2emNINlQycE1QMG8?oc=5","date":"2025-08-13","type":"pipeline","source":"Investing.com","summary":"Inovio Pharmaceuticals’ SWOT analysis: dna immunotherapy firm’s stock faces pivotal year - Investing.com","headline":"Inovio Pharmaceuticals’ SWOT analysis: dna immunotherapy firm’s stock faces pivotal year","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxQVW5zVkhWWDhyMEhKT0ZHVWRpaVh0Ny1LRGlsVDZsQm00WFI4R3FGTFA3Vks5ZjVjai14RThWVUk5dDBsNXVYX0xvSHJ5cHd5a0lXOTZiZURHNk9PeWR3QVdCUkJudG5nUWRVWkI5dEZxejRXRExPajRwZEROTnhDZ2RUcHAzNjdvTXhpa2FVeDMzOVN4N2Q3Vy1BR1dHN2JpeTVWTmhmaU0yTUlCSDZrR2lEdGltelBubzZvSW9zR0VIQlY4YnQtTGNJdU9DQUFxS25mMnlR?oc=5","date":"2025-08-12","type":"earnings","source":"PR Newswire","summary":"INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights - PR Newswire","headline":"INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTE5iUFIxQlF4S3RwTVhuVkhxT2hYYndpdC1yeUJ5U0plWGk4T0dzc0ZmbXVuVUlRWnFjakRYZWptZlh0VTVqU2R3ZXQ0MVBudjBvX080QjNQaXVOZ2VoamlTZWFWX1dKQzg?oc=5","date":"2025-07-09","type":"regulatory","source":"MarketBeat","summary":"Inovio Pharmaceuticals (INO) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $INO - MarketBeat","headline":"Inovio Pharmaceuticals (INO) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $INO","sentiment":"positive"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["BioNTech","Moderna Therapeutics","Pfizer Inc."],"therapeuticFocus":["DNA-based vaccines","Immunotherapies"],"financials":{"source":"sec_edgar","revenue":42220086,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":42220086,"period":"2017-12-31"},{"value":8787234,"period":"2017-12-31"},{"value":2644543,"period":"2017-09-30"},{"value":20412124,"period":"2017-06-30"},{"value":10376185,"period":"2017-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":54206874,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-84945901,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":74310035,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":1.08,"previousClose":1.05,"fiftyTwoWeekHigh":2.98,"fiftyTwoWeekLow":1.07,"fiftyTwoWeekRange":"1.07 - 2.98","fiftyDayAverage":1.64,"twoHundredDayAverage":1.92,"beta":1.7,"enterpriseValue":23401916,"forwardPE":-1.7,"priceToBook":3.11,"priceToSales":1354.81,"enterpriseToRevenue":358.14,"enterpriseToEbitda":-0.27,"pegRatio":0,"ebitda":-85404192,"ebitdaMargin":0,"freeCashflow":-38681548,"operatingCashflow":-88629432,"totalDebt":9367826,"debtToEquity":38.9,"currentRatio":1.4,"returnOnAssets":-57.9,"returnOnEquity":-183.5,"analystRating":"","recommendationKey":"none","numberOfAnalysts":6,"targetMeanPrice":7.63,"targetHighPrice":13,"targetLowPrice":1.8,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0.4,"institutionHeldPercent":42.2,"sharesOutstanding":81591956,"floatShares":68806606,"sharesShort":10757832,"shortRatio":15.84,"shortPercentOfFloat":15.6,"epsTrailing":-1.81,"epsForward":-0.65,"revenuePerShare":0,"bookValue":0.35,"officers":[{"age":59,"name":"Dr. Jacqueline E. Shea Ph.D.","title":"CEO, President & Director"},{"age":62,"name":"Mr. Peter D. Kies","title":"Chief Financial Officer"},{"age":60,"name":"Dr. Michael  Sumner B.S., M.B.A., M.D.","title":"Chief Medical Officer & Head of Development"},{"age":58,"name":"Dr. Laurent M. Humeau Ph.D.","title":"Chief Scientific Officer & Chairman of the Scientific Advisory Board"},{"age":null,"name":"Thomas  Hong","title":"Manager of Investor Relations"},{"age":51,"name":"Mr. Robert L. Crotty J.D.","title":"General Counsel, Corporate Secretary & Chief Compliance Officer"},{"age":null,"name":"Ms. Jennie  Willson","title":"Director of Communications"},{"age":null,"name":"Mr. E. J. Brandreth MBA","title":"Senior Vice President of Quality Assurance"}],"industry":"Biotechnology","irWebsite":"http://ir.inovio.com/","website":"https://www.inovio.com","phone":"267 440 4200"}}